Compound 1, identified as a GPR61 inverse agonist, exhibits an IC50 of 11 nM, rendering it suitable for metabolism and body weight disorder research, including obesity and cachexia [1].
Target:
Others
* VAT and and shipping costs not included. Errors and price changes excepted
